Replimune, Inc.
Clinical trials sponsored by Replimune, Inc., explained in plain language.
Biopharmaceutical company developing oncolytic immunotherapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Transplant patients with skin cancer get new hope from engineered virus
Disease control OngoingThis study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…
Phase: PHASE1, PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a tweaked herpes virus help fight cancer? early trial underway
Disease control OngoingThis early-stage trial is testing a genetically modified herpes virus called RP3, alone or combined with the immunotherapy drug nivolumab, in 123 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best…
Phase: PHASE1 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Cold sore virus turned into cancer killer? early trial underway
Disease control OngoingThis early-phase study tests a genetically modified herpes virus (RP2) in 36 adults with advanced solid tumors that have not responded to standard treatments. The virus is designed to infect and destroy cancer cells while also stimulating the immune system. Some participants also…
Phase: PHASE1 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Cancer-Killing virus combined with immunotherapy shows promise in advanced tumors
Disease control OngoingThis Phase 2 trial tests a genetically modified herpes virus (RP1) alone or with the immunotherapy drug nivolumab in people with advanced solid tumors, including melanoma, non-small cell lung cancer, and certain skin cancers. The study aims to see if the combination is safe and c…
Phase: PHASE2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Last-Resort hope: modified herpes virus plus immunotherapy for advanced melanoma
Disease control NO_LONGER_AVAILABLEThis expanded access program provides a genetically modified herpes virus (vusolimogene oderparepvec) combined with the immunotherapy drug nivolumab to adults with advanced melanoma that has worsened after anti-PD-1 treatment. The goal is to offer potential benefit to patients wh…
Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC